Welcome to the special issue of the Journal of Hematology Oncology Pharmacy (JHOP), the official publisher of the Hematology Oncology Pharmacy Association (HOPA). This special issue represents the First Annual Issue of HOPA Abstracts, 2021, and features a selection of the abstracts presented at the 17th Annual Conference of HOPA.
The abstracts featured in this issue were selected through a peer review by the HOPA Review Committee among the more than 300 abstracts that were presented at the 2021 HOPA Annual Conference on April 13-17, 2021. Because of the current pandemic restrictions, this year’s annual conference was held as a virtual meeting.
Formed in 2004, HOPA is a nonprofit, education-based organization created to help hematology oncology pharmacy practitioners and their associates to provide the best possible cancer care. HOPA’s 2004 mission statement was “to reduce the burden of cancer on society and promote optimal, cost-effective care for those affected by cancer.”
Today, HOPA supports hematology oncology research, provides education, encourages the professional development of hematology oncology pharmacists, and advocates for health policy issues that aim to improve patient care.
Currently totaling more than 3000 members, HOPA serves members in the fields of hematology oncology pharmacy, pharmacy administration, and research, and includes pharmacists, pharmacy residents, interns, and technicians specializing in hematology oncology practice.
HOPA’s mission is to support hematology oncology pharmacy practitioners and promote and advance hematology oncology pharmacy to optimize the care of individuals affected by cancer. The overarching goal of the organization is to ensure that every patient affected by cancer can have a hematology oncology pharmacist on their care team to optimize the medical care they receive.
The 20 abstracts featured in this special issue represent a sample of the hard work of pharmacists, researchers, residents, and pharmacy students in the United States and across the globe in the areas of clinical research, translational science, quality improvement, and practice management—all focused on the delivery of optimal care for the individual patient with cancer.